BridgeBio Oncology Therapeutics, Inc. (BBOT): Operating Income

Annual figures by period end, from SEC filings.

-$145.82M

Year ended 2025-12-31

2023-12-31 Operating Income (USD) 2025-12-31

Period ended	Operating Income	Change YoY	Source filing
2025-12-31	-$145.82M	n/m	2026-03-05, From 2025-01-01
2024-12-31	-$80.86M	n/m	2026-03-05, From 2024-01-01
2023-12-31	-$41.7K	n/a	2025-03-11, From 2023-01-01

Operating Income at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Operating Income	Change YoY
BridgeBio Oncology Therapeutics, Inc. (BBOT)	2025-12-31	-$145.82M	n/m
Biohaven Ltd. (BHVN)	2025-12-31	-$745.38M	n/m
BGM Group Ltd. (BGM)	2025-09-30	-$12.58M	n/m
Arcutis Biotherapeutics, Inc. (ARQT)	2025-12-31	-$12.23M	n/m
Bicara Therapeutics Inc. (BCAX)	2025-12-31	-$155.60M	n/m
MoonLake Immunotherapeutics (MLTX)	2025-12-31	-$244.83M	n/m
Enliven Therapeutics, Inc. (ELVN)	2025-12-31	-$119.66M	n/m
MapLight Therapeutics, Inc. (MPLT)	2025-12-31	-$169.08M	n/m
Rhythm Pharmaceuticals, Inc. (RYTM)	2025-12-31	-$192.02M	n/m

Compare BBOT, BHVN, BGM, ARQT side by side · Screen every company in Pharmaceutical Preparations ↗